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Summary
 
Activation of autoreactive T cells can lead to autoimmune diseases such as insulin-dependent
diabetes mellitus (IDDM). The initiation and maintenance of IDDM by dendritic cells (DC),
the most potent professional antigen-presenting cells, were investigated in transgenic mice ex-
pressing the lymphocytic choriomeningitis virus glycoprotein (LCMV-GP) under the control
of the rat insulin promoter (RIP-GP mice). We show that after adoptive transfer of DC consti-
tutively expressing the immunodominant cytotoxic T lymphocyte (CTL) epitope of the
LCMV-GP, RIP-GP mice developed autoimmune diabetes. Kinetic and functional studies of
DC-activated CTL revealed that development of IDDM was dependent on dose and timing of
antigenic stimulation. Strikingly, repeated CTL activation by DC led to severe destructive
mononuclear infiltration of the pancreatic islets but also to de novo formation of islet-associ-
ated organized lymphoid structures in the pancreatic parenchyma. In addition, repetitive DC
immunization induced IDDM with lymphoid neogenesis also in perforin-deficient RIP-GP
mice, illustrating that CD8
 
1
 
 T cell–dependent inflammatory mechanisms independent of per-
forin could induce IDDM. Thus, DC presenting self-antigens not only are potent inducers of
autoreactive T cells, but also help to maintain a peripheral immune response locally; therefore,
the induction of autoimmunity against previously ignored autoantigens represents a potential
hazard, particularly in DC-based antitumor therapies.
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M
 
any autoimmune diseases are initiated and main-
tained by sensitized and activated autoreactive T
 
cells, which destroy target cells harboring corresponding
tissue-specific antigens. In insulin-dependent diabetes mel-
litus (IDDM),
 
1
 
 T cell reactivity against a number of islet 
 
b
 
cell proteins, e.g., insulin and glutamic acid decarboxylase,
has been shown (1, 2). Genetic (3, 4) and environmental
factors, e.g., viruses (5) and superantigens (6), may contrib-
ute to the activation of self-reactive lymphocytes. How-
ever, the precise mechanisms involved in the initial sensiti-
zation of T cells are only incompletely understood. It has
been established that many self-antigens exclusively ex-
pressed by cells not reaching blood and lymphoid tissues
are possibly ignored by the immune system (7). On the
other hand, it is striking that target organs of several au-
toantibody-dependent autoimmune diseases, such as Hash-
imoto’s thyroiditis, exhibit lymphoid structures including
lymphoid follicles and germinal centers.
Antigen presentation by professional APCs, particularly
dendritic cells (DC), is of key importance for the initiation
of primary immune responses (8). This special capacity de-
rives from their ability to transport antigen from the pe-
riphery to draining lymphoid organs and accessory mole-
cules that support induction of T cell responses (9). The
potency of DC in eliciting primary immune responses in
vivo is demonstrated by studies in which immune responses
against alloantigens (10) and HY antigens (11) were in-
duced with as few as 10
 
4
 
–10
 
5
 
 DC.
Multiple lines of evidence indicate that DC may also
participate in the onset of autoimmune diseases. DC are the
first cells to infiltrate the thyroid gland during development
of thyroid autoimmune disease in BioBreeding rats (12)
and are found to establish direct contact with follicular epi-
thelium during autoimmune thyroiditis in Graves’ disease
(13). Furthermore, Knight et al. (14) showed that DC pre-
 
1
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senting thyroglobulin enhanced the development of au-
toimmune thyroiditis in genetically susceptible CBA mice.
Due to their high immunostimulatory capacity, it has
been proposed to use DC pulsed with tumor peptides or
crude tumor protein homogenates as an efficient immuno-
therapeutic means of inducing immune responses against
tumors (15, 16). However, such protocols may include the
possible consequence of autoimmune reactions when anti-
self reactions are induced, as suggested by induction of au-
toreactive T cells and vitiligo in patients with metastatic
melanoma receiving immunotherapy (17).
To investigate the involvement of DC in the initiation
and maintenance of an autoimmune disease, we used trans-
genic mice expressing lymphocytic choriomeningitis virus
glycoprotein (LCMV-GP) exclusively in pancreatic 
 
b
 
 cells
(RIP-GP mice). RIP-GP mice do not spontaneously de-
velop autoimmune diabetes, defined as hyperglycemia, in-
sulitis, and destruction of pancreatic islets, because this self-
antigen is immunologically ignored. However, these mice
develop an acute form of nonlethal autoimmune diabetes
when infected with LCMV (18, 19). Thus, in the RIP-GP,
mice lymphocytes are not deleted in the thymus and T cells
react when appropriately activated by antigen in the lym-
phoid tissues. In this model situation, where acute infection
triggers disease, primarily CD8
 
1
 
 CTL acting via perforin
and the immunostimulatory cytokine IFN-
 
g
 
 are responsi-
ble for the development of IDDM (18, 20–23). We report
here on the development of diabetes in RIP-GP and per-
forin-deficient RIP-GP mice after immunization of DC
from transgenic mice constitutively expressing the immu-
nodominant epitope GP33 of LCMV (H8-mice). Repeti-
tive injection of the antigen-expressing DC initiated an au-
toimmune response leading to destruction of 
 
b
 
 islet cells.
Interestingly, and comparable to Hashimoto’s thyroiditis in
man, evolution of this model autoimmune disease in mice
correlated with the local development of organized lym-
phoid tissues.
 
Materials and Methods
 
Mice.
 
C57BL/6 mice were obtained from the Institut für
Labortierkunde (University of Zürich). Mice expressing LCMV-GP
under the control of the rat insulin promoter (RIP-GP) and per-
forin-deficient mice crossed with RIP-GP mice (PKO 
 
3 
 
RIP-GP)
have been described previously (18, 22). Mice transgenic for a
V
 
a
 
2/V
 
b
 
8 TCR specific for H2-D
 
b
 
 and the major LCMV-GP
epitope, GP33-41 (GP33), were used as donors of transgenic T
cells (24). Transgenic mice expressing the LCMV GP33 epitope in
all tissues were generated using a construct containing the H-2K
 
b
 
regulatory elements and the coding sequence for amino acids 1–60
of the LCMV glycoprotein (H8-mice [25]). All animals were kept
under specific pathogen–free conditions. Experiments were car-
ried out with age- (8–16 wk) and sex-matched animals.
 
Viruses, Cell Lines, and Peptides.
 
LCMV-WE was originally ob-
tained from Dr. F. Lehmann-Grube (University of Hamburg,
Germany) and was propagated on L929 cells. EL-4 (H-2
 
b
 
), a
thymoma cell line, was used as target cell. LCMV GP33-41
(KAVYNFATM; GP33) was produced by Neosystem Laboratoire
(Strasbourg, France).
 
Preparation of DC.
 
Generation of DC from C57BL/6 and H8
bone marrow cultures has been described previously (26). In
brief, bone marrow was flushed from femurs and tibias and subse-
quently depleted of red cells with ammonium chloride. Bone
marrow cells were depleted of lymphocytes, B cells, and I-A
 
b
 
positive cells using a cocktail of mAbs (YTS191.1, YTS169.4.2,
RA3-3A1/6.1, B21-2) and goat anti–rat IgG–coated Dynabeads
(Dynal A.S., Oslo, Norway). Cells were plated at 0.5 
 
3 
 
10
 
6
 
/ml
in RPMI 1640 supplemented with 5% FCS, penicillin/strepto-
mycin, 10 ng/ml recombinant murine (rm)GM-CSF (supplied by
Novartis Pharma Schweiz AG, Bern, Switzerland) and IL-4–con-
taining supernatant from cell line X63-IL4 (provided by Dr. M.
Kopf, Basel Institute of Immunology, Basel, Switzerland) to a fi-
nal concentration of 100 ng/ml. At days 2 and 4 of culture, 50%
of the supernatant was removed, and fresh medium and fresh cy-
tokines were added. At day 6, nonadherent cells were collected
and further purified over metrizamide (14.5% in RPMI 1640/5%
FCS; Sigma Chemical Co., St. Louis, MO) to remove cell debris
and high density cells. The resulting DC populations showed a
purity of 80–90% as determined by cytofluorometry using mAb
against MHC class I and II antigens, costimulatory molecules
CD80 and CD86, and the DC marker NLDC-145 (not shown).
Cells were washed three times with BSS (balanced salt solution),
resuspended at 2 
 
3 
 
10
 
6
 
/ml in BSS, and serial 10-fold dilutions
were made. DC were intravenously injected in a volume of 0.5 ml.
 
Cytotoxicity Assay.
 
For detection of primary ex vivo cytotox-
icity, effector cell suspensions were prepared from spleens of im-
munized mice at the indicated time point after priming. EL-4
cells were labeled with GP33 (10
 
2
 
6
 
 M) and 250 
 
m
 
Ci 
 
51
 
Cr for 1.5 h
at 37
 
8
 
C. 10
 
4
 
 target cells per well were incubated in 96-well
round-bottomed plates with serial threefold dilutions of spleen ef-
fector cells, starting with an E/T ratio of 90:1, for 15 h. EL-4 cells
without peptide served as controls. The supernatant of the cyto-
toxicity cultures was counted in a gamma counter (Cobra II;
Canberra Packard, Berkshire, UK). Percentage of specific lysis
was calculated as (experimental release 
 
2 
 
spontaneous release)/
(total release 
 
2 
 
spontaneous release) 
 
3 
 
100. Spontaneous release
was always 
 
,
 
29%.
 
CTL Precursor Assay.
 
Quantification of GP33-specific pre-
cursor CTL (CTLp) per spleen was performed by limiting dilu-
tion analysis as described (27). Responder spleen cells were
titrated and cultured with 10
 
4
 
 LCMV-infected, irradiated perito-
neal macrophages and 10
 
5
 
 irradiated feeder spleen cells in
IMDM/10% FCS and 10% Con A supernatant using 16 wells per
dilution step. After 6 d of culture, cytotoxicity was tested on
GP33-labeled or unlabeled EL-4 cells in a standard 
 
51
 
Cr-release
assay and CTLp frequencies were calculated.
 
Cytofluorometry.
 
To detect expansion of transgenic TCR-
expressing T cells (24), peripheral blood cells, spleen cells, and
lymph node cells from hepatic lymph nodes were stained for
CD8, V
 
a
 
2, and V
 
b
 
8.1 using FITC-conjugated rat anti–mouse
CD8, PE-conjugated rat anti–mouse V
 
a
 
2a, and biotinylated rat
anti–mouse V
 
b
 
8.1 (all from PharMingen). Erythrocytes were
lysed with FACS
 
Ò
 
 lysis solution (Becton Dickinson, San Jose,
CA), and the cell suspensions were analyzed on a FACScan
 
Ò
 
 flow
cytometer (Becton Dickinson) using logarithmic scales. Viable
lymphocytes were gated using a combination of forward light
scatter and 90
 
8
 
 side scatter.
 
Immunohistology.
 
Freshly removed organs were immersed in
HBSS and snap-frozen in liquid nitrogen. Tissue sections of
5-
 
m
 
m thickness were cut in a cryostat and fixed in acetone for 10
min. Sections were incubated with anti–mouse mAb against
CD4
 
1
 
 cells (YTS191.1 [28]), CD8
 
1
 
 cells (YTS169.4.2 [28]), B 
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cells (RA3-3A1/6.1; American Type Culture Collection, Rock-
ville, MD), follicular DC (4C11 [29]); CD11c
 
1
 
 DC (30), periph-
eral node addressin (PNAd) (MECA-79; PharMingen), and poly-
clonal guinea pig antibodies against insulin (Dakopatts A/S,
Glostrup, Denmark). Alkaline phosphatase–labeled, species-spe-
cific goat antibodies (Tago Inc., Burlingame, CA) were used as
secondary reagents. The substrate for the red color reaction was
AS-BI phosphate/New Fuchsin. Sections were counterstained
with hemalum. 15–20 islets from 2–3 histological sections of each
mouse were evaluated.
 
Measurement of Blood Glucose.
 
The glucose concentration in
blood obtained from a tail vein was measured using Haemo-Glu-
cotest strips (Boehringer Mannheim, Mannheim, Germany). Mice
were considered diabetic with values 
 
.
 
14 mM at two consecu-
tive measurements.
 
Results
 
Induction of Diabetes in RIP-GP Mice by DC Immuniza-
tion.
 
To study whether DC can initiate and promote
IDDM in the RIP-GP mouse, different doses of DC from
H8-mice (H8-DC) were administered intravenously using
various protocols, and blood glucose levels were moni-
tored. With a single injection of a high dose of 10
 
6
 
 H8-
DC, mice remained normoglycemic or displayed only tran-
sient hyperglycemia with intermediate blood glucose levels
of 15–20 mM and eventually returned to normoglycemia
within a few days (Fig. 1 
 
A
 
). In some mice (2/8), blood
glucose quickly rose to values 
 
.
 
44 mM (Fig. 1 
 
A
 
), fol-
lowed by death after 4–6 d. After a single injection of an
intermediate dose of 10
 
5
 
 H8-DC, diabetes did not develop
(Fig. 1 
 
B
 
). In contrast, repetitive injection of intermediate
doses of H8-DC, i.e., three doses of 10
 
5
 
 DC in 6-d inter-
vals (Fig. 1 
 
C
 
) or four doses of 10
 
4
 
 DC in 2-d intervals (Fig.
1 
 
D
 
), caused development of diabetes. 50% of the mice re-
petitively immunized developed diabetes between days 10
and 14, whereas 40% of the mice developed hyperglycemia
later, by days 18–21. One out of eight mice repetitively
immunized with 10
 
4
 
 DC showed a transient hyperglyce-
mia, and one out of eight mice from this group remained
normoglycemic. 4 out of 16 mice repetitively immunized
with H8-DC rapidly developed diabetes and died before
day 21. This was surprising because the same mice infected
with LCMV developed diabetes (with blood glucose values
 
.
 
44 mM), but survived usually for 40 d or more (not
shown). Thus, under the conditions used, a severe and rap-
idly lethal IDDM was induced by DC, in a dose- and tim-
ing-dependent fashion.
 
CTL Activity and Expansion after Single versus Repetitive
DC Immunization.
 
To determine how dose and timing of
antigen delivery by DC influences CTL responses, CTL
activity and expansion at various time points after single
high dose (10
 
6
 
), single low dose (10
 
4
 
), and repetitive inter-
mediate doses (10
 
5
 
) of DC was monitored. Injection of a
single high dose of DC induced CTL activity by day 4, as
determined by direct ex vivo cytotoxicity in an overnight
 
51
 
Cr-release assay; maximum CTL activity was reached by
day 8 and waned between days 12 and 16. With low doses
of DC, CTL activity was lower and the period during
 
which CTL activity could be detected was shorter (Table
1). Importantly, repetitive stimulation with DC on days 0
and 8 prolonged CTL activity, leading to a weak but de-
tectable CTL activity also on day 16 (Table 1).
To follow the expansion of GP33-specific CTLp in the
spleen during the activation by DC, CTLp frequencies
were determined by limiting dilution assay. The maximal
expansion of GP33-specific CTLp was detected on day 4,
followed by a continuous decrease until day 16 (Table 1).
A 100-fold increase of DC used for immunization resulted
only in a modest elevation of CTLp in the spleen, e.g.,
1:15,000 and 1:5,000 at day 4 for 10
 
4
 
 and 10
 
6
 
 H8-DC, re-
spectively (Table 1). Repetitive inoculation of 10
 
5
 
 DC did
not further enhance CTLp frequency (Table 1).
To test whether the limited expansion of CTL after high
dose or repetitive DC immunization was due to a lack of
GP33-specific precursor cells or whether CTL leave the
spleen immediately after activation by DC, we followed
the expansion of H8-DC–activated GP33-specific TCR
transgenic CTL (24). After adoptive transfer of 5 
 
3 
 
10
 
5
 
spleen cells from TCR transgenic mice into C57BL/6
mice, 2–3% of the CD8
 
1
 
 T cells expressed the transgenic
V
 
a
 
2/V
 
b
 
8 TCR. Single DC immunization led to a maxi-
mal expansion of these cells by day 4 to 
 
z
 
8% in spleen and
blood and 5% in the hepatic lymph node (Fig. 2). Similarly,
repetitive DC administration in 2-d intervals induced max-
imal expansion on day 4, with 22% in spleen and blood and
14% in hepatic lymph nodes (Fig. 2). In both single and re-
petitive immunization protocols, TCR transgenic T cell
expansion was transient and TCR transgenic T cells per-
sisted at slightly elevated levels between 3.5 and 5% (Fig.
2). After intravenous injection, H8-DC have been shown
to migrate mainly to the spleen and, to a smaller propor-
tion, to hepatic lymph nodes (26). Thus, it is reasonable to
Figure 1. Blood glucose levels in RIP-GP mice after single or repeti-
tive intravenous immunization with H8-DC. Mice were immunized with
either a single dose of (A) 106 DC (n 5 8) on day 0 or (B) 105 DC (n 5 4)
on day 0, or repetitive doses of (C) 105 DC (n 5 8) on days 0, 6, and 12
or (D) 104 DC (n 5 8) on days 0, 2, 4, and 6. Arrows, Day of DC injec-
tion. Values of four representative mice per group are shown. 
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assume that GP33-specific T cells were first activated and
expanded by H8-DC in spleen and hepatic lymph nodes
and subsequently entered the blood to emigrate into pe-
ripheral nonlymphoid tissues.
 
Cellular Composition and Organization of DC-induced
Autoimmune Lesions.
 
Using immunohistochemical analysis,
we evaluated the cellular composition and organization of
pancreatic infiltrates in the course of DC-induced auto-
immune diabetes. To this end, RIP-GP mice were immu-
nized intravenously at days 0, 6, and 12 with 10
 
5
 
 H8-DC,
and pancreata and submandibular salivary glands were ana-
lyzed on days 7, 14, and 21 for the presence of CD8
 
1
 
 and
CD4
 
1
 
 T cells, B220
 
1
 
 B cells, F4/80
 
1
 
 macrophages, CD11c
 
1
 
DC, and insulin-producing islet cells. Mice analyzed by
immunohistochemistry on day 7 were normoglycemic,
whereas mice analyzed on day 14 had been hyperglycemic
for 1–2 d (blood glucose 17–25 mM), and mice analyzed
on day 21 had been hyperglycemic for at least 7 d (blood
glucose 
 
.
 
44 mM). At the early time point, CD8
 
1
 
 T cells
infiltrating the pancreatic islets clearly outnumbered CD4
 
1
 
T cells, and B cells were barely detectable (Fig. 3, 
 
A1
 
–
 
5
 
).
Interestingly, APCs characteristic of lymphoid organs could
be detected in these early infiltrates. Particularly DC stain-
ing positive with N418, an antibody that stains the gp150/
90 
 
a
 
x
 
 integrin CD11c (30), were found in the infiltrates
(Fig. 3 A5). F4/801 macrophages were less abundant in
these early infiltrates (not shown). The infiltrates were al-
ways associated with insulin-positive islets or periductal in
their close proximity (Fig. 3, A1–5). At day 14, more cells
had infiltrated the insulin-producing islets, particularly
CD41 T cells, B cells, and N4181 dendritic cells (Fig. 3,
B1–5). Correlating with the increased infiltration by im-
mune cells, staining for insulin decreased (Fig. 3 B1), indi-
cating the progressive destruction of islet cells. By day 21,
infiltrating cells had nearly completely replaced islet cells
(Fig. 3, C1–5). Control stainings of submandibular salivary
glands in DC-immunized RIP-GP mice (Fig. 3 D) and
liver and pancreas sections of DC-immunized C57BL/6
mice (not shown) showed only a few scattered CD81 and
CD41 T cells. A striking finding was the formation of lym-
phoid structures in close proximity to remaining insulin-
producing islets (Fig. 4). These newly formed lymphoid
tissues were found mainly periductally in the pancreatic pa-
renchyma (Fig. 4 A, arrow), whereas pancreatic lymph
nodes were clearly located outside of and loosely attached
to the pancreas (Fig. 4 A, arrowhead). CD41 T cell infiltrates
were found in insulin-positive islets as well as in the newly
formed lymphoid structures (Fig. 4 B). In contrast, B cell
infiltrates were detected mainly in the periductal lymphoid
structures (Fig. 4 C), where they showed distinct compart-
mentalization particularly with CD81 T cells (Fig. 4, E and
F), comparable to that of peripheral lymphoid organs. Cells
staining with 4C11, an antibody specific for follicular DC,
were restricted to the newly formed lymphoid tissues and
Table 1. Primary Activity and Frequency of GP33-specific CTL in Spleen after Immunization with H8-DC
Single immunization
Repetitive
immunization
Group day 4 day 8 day 12 day 16  day 16
106 H8-DC CTL activity 35 6 5 81 6 7 25 6 32  6  1 n.d.
CTLp frequency 1/5,000 1/18,000 1/51,000 1/63,000 n.d.
105 H8-DC CTL activity n.d. 74 6 6 n.d. 2 6 1 34 6 5
CTLp frequency n.d. 1/22,000 n.d. 1/73,000 1/83,000
104 H8-DC CTL activity 7 6 2 59 6 84  6  11  6  0 n.d.
CTLp frequency 1/15,000 1/45,000 1/60,000 1/119,000 n.d.
C57BL/6 mice were immunized intravenously at day 0 (single immunization) or at days 0 and 8 (repetitive immunization) with different numbers of
H8-DC. At the indicated time point, effector spleen cells were prepared (three mice per group), and an overnight 51Cr-release assay was performed
as detailed in Materials and Methods to determine DC-induced CTL activity and a limiting dilution assay was done to assess the CTLp frequency.
CTL activity is shown as mean specific target cell lysis 6 SD at an E/T ratio of 90:1. Data from one of three experiments are shown. n.d., Not done.
Figure 2. Expansion of GP33-specific TCR transgenic T cells by H8-
DC. 5 3 105 spleen cells from TCR transgenic mice were adoptively
transferred into C57BL/6 mice on day 21. Mice were immunized intra-
venously once with (A) 105 H8-DC on day 0 or repetitively with (B) 105
H8-DC on days 0, 2, 4, and 6. The expansion of the TCR transgenic T
cells in blood, spleen, and hepatic lymph nodes (hep. Ln) was followed by
three-color FACSÒ analysis and is depicted as percentage of Va21
Vb8.11 (tg-TCR1) cells in the CD81 compartment (mean of three ani-
mals per time point). Arrows, Day of injection of H8-DC. Data from one
of two experiments are shown.1497 Ludewig et al.
colocalized with B cells (Fig. 4, G and H). Their presence
in the DC-induced pancreatic infiltrates is particularly in-
teresting, since follicular DC are involved in B cell Ig-
switch, affinity maturation, and memory. PNAd, an adhe-
sion molecule found on endothelial cells in peripheral
lymph nodes and involved in recirculation of lymphocytes
into peripheral lymphoid tissues, was expressed in blood
vessels in the periductal organized lymphoid structures (Fig.
Figure 3. Immunohistological analysis of pancreatic islets and submandibular salivary glands in RIP-GP mice after H8-DC immunization. 105 H8-DC
were adoptively transferred on days 0, 6, and 12, and pancreata were analyzed on day 7 (A), day 14 (B), and day 21 (C) for the presence of insulin-pro-
ducing islet cells, CD81 and CD41 T cells, B2201 B cells, and CD11c1 DC. Pancreas sections from untreated RIP-GP mice were also stained but were
essentially negative except for insulin. (D) Control staining of submandibular salivary gland of a diabetic RIP-GP mouse on day 14 with the respective
markers. Original magnification: 3100.1498 DC-induced Autoimmunity
4 I). Pancreatic endothelial cells outside these lymphoid
structures did not express PNAd.
It has been shown previously that MHC-restricted
destruction of b cells by perforin-dependent CTL is an
important initiating event for autoimmune diabetes in
RIP-GP mice (22). To evaluate whether contact-depen-
dent T cell cytotoxicity is involved in DC-induced auto-
immune diabetes, we studied perforin-deficient RIP-GP
mice (PKO 3 RIP-GP; reference 22). 45% of the PKO 3
GP mice that were repetitively immunized with H8-DC de-
veloped diabetes between days 12 and 18 (Table 2). Immu-
nohistological analysis revealed that all PKO 3 RIP-GP mice
developed insulitis with .50% of the islets affected. Further-
more, PKO 3 RIP-GP mice rapidly progressed to diabetes
and, like perforin-competent RIP-GP mice, showed lym-
phoid neogenesis in periductal areas in proximity to remain-
ing insulin-producing islet cells (summarized in Table 2). In
contrast to this and confirming earlier results (22), LCMV in-
fection of RIP-GP mice with a disrupted perforin gene did
not lead to the development of autoimmune diabetes (Table
2). These mice showed a pronounced peri- and intrainsular
infiltrate; however, some islet cells remained intact, and lym-
phoid neogenesis did not develop (Table 2). Taken together,
these results show that DC immunization with the appropri-
ate self-antigen leads to destructive autoimmune diabetes ac-
companied by local formation of organized lymphoid tissues.
Figure 4. Organization of newly formed lymphoid tissues in RIP-GP mice after repetitive priming with H8-DC. Pancreata were analyzed by immu-
nohistochemistry on day 21 by staining for the indicated markers. (A) Newly formed organized lymphoid tissue was found periductally in the pancreatic
parenchyma (arrow); a pancreatic lymph node located outside the pancreatic parenchyma is also shown (arrowhead). Distribution of infiltrating (B) CD41 T
cells and (C) B cells in islets and newly formed lymphoid tissues. (D) Magnification of the boxed area in A showing an insulin-positive islet (arrow) and
periductal, de novo–formed lymphoid tissue (arrowhead) in close vicinity to an artery (*). Distinct spatial distribution of (E) CD81 T cells, (F) B cells, and
(G) follicular DC (FDC) in the newly formed lymphoid tissue. (H) Magnification of the boxed area in G showing the 4C111 follicular DC network. (I)
Staining for PNAd. The region corresponding to the boxed area in G was photographed showing PNAd1 blood vessels in the newly formed lymphoid
tissue. Original magnifications: A–C, 324; D–G, 363; H and I, 3250.1499 Ludewig et al.
Discussion
A major question in the pathogenesis of autoimmune
disorders is to define the triggering events leading to activa-
tion of previously indifferent but potentially autoreactive T
cells. Expression of the LCMV-GP in pancreatic b cells us-
ing the rat insulin promoter (RIP-GP mice) allowed us to
study the role of virus infections as possible triggers for
breaking tolerance against peripheral self-antigens leading
to destruction of pancreatic islets (18, 19). Development of
virus-induced autoimmune diabetes in RIP-GP mice is
largely dependent on the number of activated self-reactive
CTL; e.g., only double-transgenic mice expressing the
LCMV-GP in the pancreas and a GP33-specific TCR on
many of their CTL (RIP-GP 3 TCR), but not single
transgenic mice (RIP-GP), become acutely diabetic after
infection with the less immunogenic LCMV-GP recombi-
nant vaccinia virus, whereas both develop diabetes upon
LCMV infection (20). Therefore, it is surprising that im-
munization of RIP-GP mice with DC constitutively ex-
pressing the endogenous peptide led to development of a
slow form of clinically manifest and rapidly lethal diabetes,
despite the fact that they induced 10–100-fold lower CTL
activity and CTLp frequencies compared with LCMV in-
fection (26). Although this lower response corresponded to
about that induced by LCMV-GP recombinant vaccinia
virus, the data here suggest that the CTL stimulation by re-
petitive DC immunization was an important prerequisite
for the eventual progression to IDDM. Thus, with the
number of autoreactive cytotoxic T cells (18, 20), the dura-
tion of antigenic stimulation by professional APCs, i.e., the
integral of CTL activity over time, determines the disease
outcome in this model of autoimmune diabetes. Although
perforin usually plays a key role also in the induction of
acute diabetes in the RIP-GP model (22), repetitive im-
munization with GP33-presenting DC overcame the need
for perforin in causing diabetes in 45% of the mice.
Cell types normally found in peripheral lymphoid tissues
were present in DC-induced islet infiltrates and in periduc-
tal lymphoid structures, including T cells, B cells, bone
marrow–derived APCs, i.e., DC, and macrophages with a
distinct compartmentalization into T and B cell areas. Fol-
licular DC were found exclusively in these newly formed
lymphoid structures, suggesting their functional involve-
ment in local B cell responses. Only mice developing early
infiltrations and de novo formation of lymphoid follicles
developed diabetes, suggesting that autoimmunity is linked
to lymphoid neogenesis in the target organ. Similarly, de
novo formation of lymphoid tissue can be observed in mice
expressing lymphotoxin-a under the control of the RIP
(31); however, despite massive pancreatic infiltrates, these
mice do not develop diabetes (32). Therefore, it seems
likely that the appropriate and repeated activation of CTL,
e.g., via DC, together with development of lymphoid
structures in the target organs, plays a major role in the de-
velopment of destructive autoimmunity.
Human IDDM is often associated with chronic infiltra-
tion of mononuclear cells in the diseased tissue, leading to
tissue destruction (33, 34) and occasional development of
lymphoid structures (35). Additional evidence for the pos-
sible involvement of DC in the induction of IDDM comes
from the nonobese diabetic (NOD) mouse model. In pre-
diabetic NOD mice, DC form an organized network in
and around pancreatic islets, facilitating efficient stimulation
of infiltrating lymphocytes (36). Taken together, the pre-
sented and the discussed findings suggest that DC are not
only crucially involved in the initiation of an anti-self im-
mune response but are also essential for the maintenance of
autoimmune lesions in peripheral organs. Several antibody-
dependent organ-specific autoimmune diseases (including
Hashimoto’s thyroiditis and IDDM) and the data shown
here support the notion that peripheral self-antigen, usually
Table 2. Development of Insulitis, Diabetes, and Lymphoid Neogenesis in RIP-GP and PKO 3 RIP-GP Mice after DC Immunization
Immunization protocol* Recipient mice Incidence of diabetes‡ Assessment of insulitis§ Lymphoid neogenesisi
Repetitive H8-DC RIP-GP 14/16 111 Yes
Repetitive H8-DC PKO 3 RIP-GP 7/16 11 or 111 Yes
LCMV-WE PKO 3 RIP-GP 0/4 111 No
Single H8-DC RIP-GP 3/8 11 to 111 Yes
Repetitive B6-DC RIP-GP 0/3 2 No
Repetitive H8-DC C57BL/6 0/3 2 No
*Mice were immunized intravenously either repetitively with 105 DC on days 0, 6, and 12 or with 104 DC on days 0, 2, 4, and 6; single intravenous
injection was with 106 DC on day 0; 200 PFU LCMV (WE strain) were given on day 0.
‡Mice were scored diabetic with blood glucose .14 mM on two consecutive measurements.
§Insulitis was classified on day 21 by immunohistochemistry as strong (111) with severe destructive infiltration in .90% of the islets, moderate
(11) with destructive infiltration in 50–90% of the islets, and weak (1) with ,50% destructive infiltration and mainly periinsular and perivascular
infiltration; 2, no insulitis. Two to five mice were evaluated per group. 15–20 islets were evaluated from 2–3 histological sections per mouse.
iCriteria for lymphoid neogenesis by day 21: massive infiltration with T cells, B cells, CD11c1 cells, and organized lymphoid structure. Two to five
mice were evaluated per group.1500 DC-induced Autoimmunity
ignored by the immune system, can trigger an immuno-
pathological, autoimmune response if the antigen enters
draining organized lymphoid tissues in sufficient quantity
and for a sufficient time. This autoimmune response is
transient if antigen ceases to reach organized lymphoid tis-
sues. It is maintained if sufficient antigen reaches draining
lymphoid organs, or, alternatively, if lymphoid tissue is
formed within the target organ itself.
These results may impinge on our rationales to use re-
petitive immunization with DC against tumors. Due to
their high immunostimulatory capacity and their efficient
migration into organized lymphoid tissues, autologous DC
are well suited for immunization against tumors (15, 16). In
mice, antitumor immunity can be induced using DC exog-
enously pulsed with tumor-derived peptides (37), prein-
cubated with crude tumor cell preparations (38, 39), trans-
fected with tumor cell-derived mRNA (39, 40), infected
with recombinant viruses (41, 42), or by fusion of DC with
tumor cells (43). By presenting tumor antigens together
with other self-antigens by DC or by using tumor antigens
that are not exclusively expressed on tumor cells, there is a
potential of inducing undesirable anti-self responses, as ex-
emplified in this study. Therefore, it may be important to
use antigens solely expressed on tumor cells for DC-based
anti-tumor therapy to avoid possible autoimmune compli-
cations.
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